RxDoctor Payments Data

Kris Peterson, MD

Child & Adolescent Psychiatry · Lakewood, WANPI 1932284460

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $89,013 of the $105,423 with a category attached, or 84.4%. Johnson & Johnson accounts for 98.9% of it on its own, with 3 other manufacturers making up the rest. Among child & adolescent psychiatry clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$105,423in general payments, 2019–2025

Across 186 payments — averaging $566.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$104K
  • Brainsway USA Inc$880
  • Neurocrine Biosciences, Inc.$123
  • Janssen Scientific Affairs, LLC$122

What the payments were for

  • Speaking & faculty fees$89,01384%
  • Travel & lodging$12,09611%
  • Food & beverage$4,3154%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$105,423 in reported general payments places this provider in the 95th percentile of 45 child & adolescent psychiatry providers in Washington.

See all child & adolescent psychiatry providers in Washington

Medicare billing

Part B allowed, 2024
$598,892
Medicare patients
82
Services billed
2,141

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl14$16,525
Bupropion XlBupropion Hcl46$1,540
Duloxetine Hcl19$1,337
Lamotrigine ErLamotrigine13$1,123
Aripiprazole29$688
Escitalopram Oxalate23$562
Clonazepam31$539
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine19$433
Trazodone Hcl14$211
Lamotrigine11$149
Prazosin Hcl13$52

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$104,297$16,52514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 45 child & adolescent psychiatry providers in Washington.

Other child & adolescent psychiatry in Lakewood

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →